This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
This was a retrospective comparative study where the study groups were not evaluated concurrently but in two distinct (both retrospective) timeframes. The study was carried out in a single centre (the Yale-New Haven Hospital). The patients were allocated to the study groups according to the inclusion phase in the study (PIP or IP) . The length of follow-up was not explicitly stated. However, it appears to have been reasonably short.
Analysis of effectiveness
All of the patients included in the initial study sample were taken into account when estimating the effectiveness. The health outcomes used in the analysis were: the mean number of days of neutropenia after starting G-CSF, the mean number of days with leukocytosis after starting G-CSF, the mean number of days to G-CSF therapy after hospitalisation, and the average length of hospital stay after starting G-CSF.
The two study groups were shown to be comparable at baseline for demographic and clinical conditions, although those in the IP group had a lower CD4 count.
Effectiveness results
The mean number of days of neutropenia after starting G-CSF was 1.1 in the PIP group and 1.0 in the IP group, (p>0.05).
The mean number of days with leukocytosis after starting G-CSF was 0.44 in the PIP group and 0.17 in the IP group, (p<0.01).
The mean number of days to G-CSF therapy after hospitalisation was 6.8 in the PIP group and 7.4 in the IP group, (p>0.05).
The average length of hospital stay after starting G-CSF was 13.8 days in the PIP group and 11.9 days in the IP group, (p>0.05).
Clinical conclusions
The effectiveness analysis showed that the new guidelines were effective in reducing the number of days with leukocytosis after starting G-CSF. The new guidelines did not increase the length of hospitalisation.
Measure of benefits used in the economic analysis
The health outcomes were left disaggregated and no summary benefit measure was used in the economic evaluation. A cost-consequences analysis was therefore carried out.
Direct costs
Discounting was not relevant due to the short time horizon of the study and it appears not to have been conducted. The unit costs were not reported separately from the quantities of resources used. The health services included in the economic evaluation appear to have been only the G-CSF drugs used. The cost/resource boundary adopted in the study was not explicitly stated, but was likely to have been that of the hospital. Resource use was estimated using actual data coming from the same patients as those involved in the effectiveness study. The costs were estimated from the hospital billing database. No price year was reported.
